PubMed Health⌕ Search

Biomedical subjects

A Colichón

Publications and source records attributed to A Colichón.

7 recordsLinked to original sources
PubMed1990

[Serologic response to a DNA recombinant vaccine against hepatitis B in natives of the Peruvian Amazonian jungle].

Large areas of the Amazon basin in Brazil, Colombia, Ecuador, and in the nonoriental region of the peruvian jungle have been found to be hyperendemic to Hepatitis B with high prevalence of asymptomatic carriers (11 to 25%) and, in more selected areas, Hepatitis Delta has been also reported. In the present report, we have studied 108 volunteers from six different Jivaroes communities living in a hyperendemic Hepatitis B area. They received 2 doses of DNA recombinant yeast derivated HBV vaccine. All the selected persons were HBsAb negatives, but many (80%) had antibodies to HBc. Following immunization schedule, 80% responded with the formation of HBsAb; a better seroconversion was achieved in those negatives to anticore IgG compared with those having HBcAb. We obtained 90% of seroconversion in spite of the fact that our vaccination schedule was prolonged up to 10 months from the one recommended by the manufacturer. The vaccination schedule 0,4, 14 months, and the schedule 0,4 months, had 76 and 29% of seroconversion, respectively. We want to point out three observations: 1) It is quite possible that many of the Anti-core positives, that did not respond to vaccination were carriers of HBsAg undetectable by the conventional EIA test carried out; 2) The seroconversion rate in these natives was low (up to six months after the vaccination schedule); and 3) Many of the HBcAb were false positives and many of them were recently infected. We conclude: A) It is highly important to assess the anti-HBs hyperendemic areas before attempting vaccinations; B) All persons negative to anti-HBs should be vaccinated in spite to anticore antibodies; C) Areas with difficult access could be vaccinated even until 10 months without affecting good results, and D) DNA recombinant vaccine (ENGERIX B) was well tolerated. No side effects were observed.

Adolescent↗
PubMed1989

[Prevalence of serologic markers of hepatitis B among health and administrative staff at a general hospital of the Peruvian jungle].

A seroepidemiological assessment for Hepatitis B was performed in 199 workers, apparently healthy, of Hospital de Apoyo Iquitos of them were health care workers (representing 29.96% of health workers) and 42 were administrative personnel (22.82% of hospital's administrative personnel). We evaluated the HBsAg and anti-HBc IgG total by the microelisa technique. The total prevalence of HBsAg carriers was 3.36% and 20.1% of the anti-HBc; in the health group the 3.89% had HBsAg and the 16.88% anti-HBc, while the administrative group presented 2.38% of HBsAg and 26.19% the anti-HBc. There was no significative statistical difference between both groups. There was not either in the presence of the different studied epidemiological variables. We presume that it can exist a common epidemilogical factor which would conditioned a similarity of risk for infection in the health personnel as well the administrative personnel and even in the general population. If this find in other Amazon cities is confirmed, we could conclude that this represents a epidemilogical characteristic of the intermediate endemicity urban areas.

Adult↗
PubMedDate not supplied

[The serological response to a recombinant DNA vaccine in the native residents of 2 hyperendemic hepatitis B areas in the Peruvian Amazonia].

UNLABELLED: In large areas of the Amazon jungle from Brazil, Colombia, Venezuela and Peru, it has been reported hyperendemic HBV and delta focus. In the Peruvian jungle we found up to 97% of prevalence of HBV, on the northern Jívaro tribes vs the southern tribes, Arawak, (65%). In this paper we studied 226 volunteers from 6 Jívaro and 3 Arawak villages, who accepted to be vaccinated with a DNA recombinant vaccine (ENGERIX B); all of them were previously HBsAg/Ab negatives but 55.5% of them were anti-core (IgG) positive. Our results show 84.9% of seroconversion to anti-HBs, and 73.5% was consider to be immunized (> 10 mIU/ml). Better response was observed in those that were HBcAb negative, coming from a low endemic area. We also observed a good vaccine response although we had to change months the response decreased up to 51.8% of seroimmunity. Higher anti-HBs titles was observed in the southern tribes: MGC of 416.3 mIU/ml. compared with the south: MGC: 182.2 mIU/ml. CONCLUSIONS: It is important to check previously, in hyperendemic areas, HBV markers, specially. It is important to receive the second dose between with the third dose up to 14 month. The immune response overall was good: the ABsAb titles obtained was in average, 290 mIU/ml (10.2-41,00). Apparently the vaccine do not suffer during the difficulties in transportation in the jungle. No side effects we shown during the vaccination program.

Adolescent↗